IBD Versus IBS: How the Two Are Told Apart

Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) can produce the same daily complaints, cramping, urgency and altered stool, yet they are biologically different: IBD involves visible, measurable inflammation of the gut wall, while IBS is a disorder of gut function with no such tissue damage. The most useful non-invasive tool for separating them is fecal calprotectin, a protein released by white blood cells that rises when the intestinal lining is inflamed. A low result makes IBD unlikely and can spare a person a colonoscopy; a high result raises suspicion enough to justify one. The value of that single number, though, depends heavily on the cutoff chosen and on how likely the disease was before the test was ever run.

Same symptoms, different biology

IBS is defined by symptom patterns and by the absence of a structural cause. IBD, meaning Crohn's disease and ulcerative colitis, is defined by chronic inflammation that a camera and biopsy can see. The clinical difficulty is that at the bedside the two overlap. Weight loss, blood in the stool, nighttime symptoms, anemia and a strong family history push toward IBD, but many patients with genuine IBD look unremarkable early on, and many with IBS carry alarming-sounding symptoms that turn out to be functional. That is why a laboratory marker reflecting the tissue itself, rather than how the patient feels, is worth having.

What calprotectin actually measures

Calprotectin is a calcium-binding protein that makes up a large share of the contents of neutrophils, the white cells recruited to inflamed tissue. When neutrophils migrate into an inflamed intestinal wall and are shed into the gut, calprotectin ends up in stool in proportion to the degree of inflammation. Because IBS does not involve this neutrophilic inflammation, calprotectin stays low. As Walsham and Sherwood describe in their 2016 review in Clinical and Experimental Gastroenterology, the marker is stable in stool for days, which makes it practical to collect at home and send to a lab. The most widely quoted decision threshold, 50 micrograms per gram, traces back to early work at King's College Hospital and is the figure most manufacturers still print.

Sensitivity, specificity, and the cutoff trade-off

A screening test earns its keep by ruling things out. In their 2010 BMJ meta-analysis, van Rheenen and colleagues pooled diagnostic studies and reported roughly 93 percent sensitivity and 96 percent specificity for calprotectin in identifying IBD in adults. High sensitivity is the property that matters most for triage, because it means few true cases are missed, so a negative result can be trusted. Their modeling suggested that using calprotectin to decide who needs endoscopy could cut the number of adults sent for the procedure by about two thirds, at the cost of missing roughly 6 percent of IBD cases. That is an explicit trade, not a free lunch.

Where you set the line changes the answer

The 50 microgram cutoff is not sacred. Push it lower and sensitivity climbs while specificity falls, so fewer cases slip through but more healthy people get flagged and sent for scopes they did not need. Push it higher, and some labs use 100 or 150, and the opposite happens. The systematic review and economic evaluation led by Waugh for the UK Health Technology Assessment program found that, in adults, laboratory calprotectin separated IBD from IBS with about 93 percent sensitivity and 94 percent specificity at the 50 cutoff, while individual studies ranged from 83 to 100 percent sensitivity and 60 to 100 percent specificity. That spread is the honest picture. The grey zone between clearly normal and clearly abnormal is real, and results landing there often call for a repeat test or further assessment rather than an immediate verdict.

Pretest probability does half the work

A test result is not an answer on its own; it updates a probability you already held. In primary care, where most abdominal complaints are functional and IBD is uncommon, a negative calprotectin is powerfully reassuring, because the disease was unlikely to begin with and the high sensitivity drives the remaining probability close to zero. The same negative result in a young patient with weight loss, rectal bleeding and anemia should carry less reassurance, because the pretest probability was high enough that no single stool marker can dismiss it. This dependence on prevalence is why predictive values move around. In a hospital case series by Fu and colleagues, published in Scientific Reports in 2017, calprotectin at the 50 cutoff showed about 76 percent sensitivity and 93 percent specificity, with a positive predictive value near 97 percent but a negative predictive value of only about 53 percent, precisely because that population was enriched for genuine disease. The same test looks very different depending on who is being tested.

What the number cannot settle

Calprotectin marks inflammation, not IBD specifically. It also rises with intestinal infections, with regular use of nonsteroidal anti-inflammatory drugs, with some polyps and cancers, and it behaves less reliably in very young children. A single elevated result therefore says "something inflammatory is happening here, look further," not "this is Crohn's disease." Walsham and Sherwood note that performance in unselected primary care is lower than in specialist clinics, roughly 82 percent sensitivity and 77 percent specificity in one large primary care cohort, another reminder that the setting shapes the meaning. The marker triages; the colonoscopy and biopsy still decide.

The practical shape of the workup

Put together, the modern approach is layered. Symptoms and alarm features set the initial suspicion. Calprotectin then sorts the ambiguous middle: a clearly low value in a low-risk person supports a functional diagnosis and avoids an invasive test, while a clearly high value, or any high-risk presentation regardless of the marker, earns a look inside. This is an educational overview and not medical advice; anyone with persistent digestive symptoms, bleeding or weight loss should be evaluated by a qualified clinician who can weigh the whole picture.